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Abstract: The confluence of nanotechnology and biotechnology provides significant commercial 
opportunities. By identifying, classifying and tracking firms with capabilities in both 
biotechnology and nanotechnology over time, we analyze the emergence and evolution of the 
global nanobiotechnology industry.  
Research in nanotechnology has expanded rapidly in the last 15 years, but the development of 
commercial products has been significantly slower1-3. One of the most promising areas for 
commercialization is the application of nanotechnology to biological processes4-6. This is due, in 
part, to the fact that it involves the confluence of two previously disparate research fields – 
nanotechnology and biotechnology – and novel combinations of ideas and approaches are 
known to increase the opportunities for innovation7,8. 
The rate of increase in nanobiotechnology invention is well documented9,10.  However, little is 
known about the commercialization of these inventions and the entry of firms into the field.  For 
example, what types of companies have both biotechnology and nanotechnology capabilities, 
when and where did they develop them, and what applications are they targeting? And are 
these companies actually integrating nanotechnology with biotechnology? Here we explore the 
emergence of the global nanobiotechnology industry by identifying, tracking and analysing firms 
with capabilities in biotechnology and nanotechnology, and examining the degree to which they 
integrate their knowledge. 
Entry and exit of nanobiotechnology firms 
Through longitudinal analysis and an extensive search and validation process, we identified 507 
firms globally targeting human health that have both biotechnology and nanotechnology 
capabilities. We categorized our sample by firm type, location, and industry sub-sector.  We 
then tracked the entry and exit of these firms, including mergers and acquisitions. Details on our 
methodology are available in the supplementary information accompanying this paper online.  
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Our analysis shows that nanobiotechnology capabilities first emerged in multinational 
corporations in the 1980s and early 1990s (Fig. 1). Most of these multinational corporations are 
based in the chemical (Dow, Bayer, for example), pharmaceutical (Roche, Abbott Labs, for 
example) or the electronics (HP, Hitachi, for example) industries. Most have developed 
capabilities in biotechnology and nanotechnology in separate subsidiaries and have 
supplemented their capabilities by acquiring smaller nanobiotechnology firms. By 1990, there 
were already 10 multinational corporations with both biotechnology and nanotechnology 
capabilities (Fig. 1).  (In fact, research areas such as liposomes, which are now considered to 
be within the realm of nanotechnology, have existed in polymer chemistry research since the 
1960s.) Specific nanobiotechnology applications began to emerge in the early 1990s.  
As of 1999, the majority of the firms in the emerging nanobiotechnology sector were de novo 
firms, which we define as new ventures founded specifically to commercialize the opportunities 
arising from the confluence of biotechnology and nanotechnology. De novo firms rapidly 
increased in number between 1995 and 2007 (Fig. 1), with a total of 215 entries during that time 
period. The timing of these entries is consistent with the claim that new ventures are more likely 
than large, established firms to attempt to commercialize highly uncertain technologies4,11,12. In 
the emerging nanobiotechnology industry, approximately two-thirds of the firms with 
nanobiotechnology capabilities are very small as measured by annual revenues4,13.  Therefore, 
ventures can be considered the primary driver for innovation in such highly diverse fields. One 
prominent nanobiotechnology inventor and entrepreneur stated that he needed to form new 
ventures because when he licensed his diverse technologies to large firms they often did not 
develop these technologies further12. A de novo example is depicted in Box 1. Our data also 
showed a steep decline in the number of de novo entrants during and after 2008 and an 
increase in the number of de novo exits in the same period. It is likely that this reflects financing 
constraints during the period15. 
We define de alio as incumbent firms that have chosen to enter the nanobiotechnology industry. 
De alio firms are differentiated from multinational corporations because they are smaller in size, 
have fewer (or no) subsidiaries, and have much less geographic scope. De alio firms are often 
established biotechnology firms, which enter the nanobiotechnology industry through 
development of their own capabilities in nanotechnology or by acquiring existing firms that have 
demonstrated success in integrating biotechnology and nanotechnology. We find that the de alio 
firms started entering this industry in increasing numbers after 1998 – following the FDA 
approval of the first nanobiotechnology drug Doxil® in 1995 – with a peak in the year 2005.   
After a period of fewer entries after 2008, another increase was observed in 2011 (Fig. 1).  
Although multinational corporations have significant nanotechnology capabilities, we find that 
their focus remains on their existing industries and technologies: only a very small proportion of 
their total patents can be classified as nanobiotechnology (on average 0.1%, compared with an 
average of 9.9% for de novo firms and 3.0% for de alio firms). This highlights the tensions 
between existing capabilities and emerging capabilities within large, established organizations, 
such as the pressures suppressing radical innovation in the multinational chemicals corporation 
Degussa11. Therefore, despite first-mover advantages and superior resources of multinational 
corporations, it is the small, fledgling experiments, in the form of de novo firms tightly integrated 
to universities, which appear most likely to cross-pollinate concepts from different disciplines 
and commercialize the resulting nanobiotechnology inventions.  
Industry evolution across countries and regions 
Based on existing innovation literature16, we expected national and regional differences in the 
evolution of the global nanobiotechnology industry. Similar to other technology based industries, 
the evolution of the nanobiotechnology industry globally has not been homogeneous. As 
depicted in Fig. 2, we find that the US leads the emergence of this industry, with approximately 
60% of global firms located there. Predominant regional strengths in nanobiotechnology are 
found in California, Massachusetts, and New York & New Jersey.  Somewhat surprisingly, the 
rest of the US also has a substantial and growing proportion of nanobiotechnology firms, outside 
of traditional biotech clusters. For example, the integrative nanobiotechnology diagnostics 
venture, Nanosphere (see Box 1), was spun out of Northwestern University and is building its 
manufacturing facilities in Northbrook, Illinois. This suggests that star scientists in research 
universities are the most important determinant of the location of new nanobiotechnology firms, 
as was previously observed for the formation of the biotechnology industry in the 1970s and 
1980s17.  Elsewhere in North America, Canada has built a presence, with 15 nanobiotechnology 
firms as of 2011. 
Europe holds more than a quarter of the global nanobiotechnology firms, with Germany, the UK 
and France all having established a significant presence in the emerging industry. Germany, 
with 35 firms as of 2011, has been the leading European country throughout the evolution of the 
nanobiotechnology industry, although their relative share within Europe has decreased from 
37% to 24% between 2005 and 2011 (Fig. 2). As in the US, the entry of nanobiotechnology 
firms outside of the traditional biotech clusters in Europe has been extensive and continued 
through the financial crisis. Several countries such as Sweden, Netherlands, Spain and Italy 
have new entrants between 2008 and 2011.  France is an interesting case, with minimal 
nanobiotechnology activity in 2005, but 14 firms by 2011, with a predominance of de novo drug 
delivery firms.   
The leading nanobiotechnology country in Australasia and Asia is Japan, with 23 firms as of 
2011. Australia, New Zealand, South Korea, China, Israel and India also have a presence. The 
Australasia-Asia region accounted for 14% of global nanobiotechnology firms in 2011. There 
was rapid growth in firm entry from 2005 to 2008, and slower growth since 2008, but little 
change in this region’s global share during that time.   
Overall, it can be seen that the global nanobiotechnology industry underwent rapid growth 
before 2008 (a 51% increase in the total number of firms between 2005 and 2008), but slowed 
down substantially after 2008 (a 17% increase in the total number of firms between 2008 and 
2011). Regions have evolved in notably different ways. Massachusetts firms, for example, 
represent all subsectors of nanobiotechnology and have a roughly equal mix of de alio and de 
novo firms.  France, on the other hand, has fostered impressive growth in a focused 
nanobiotechnology subsector, suggesting that purposeful science policy can play an important 
role in this emerging industry. 
Industry evolution by subsector 
The nanobiotechnology industry consists of several subsectors with notable differences in 
application focus. Table 2 provides an example of the types of firms that are categorized in each 
nanobiotechnology industry subsector. Following studies of industry evolution that track firm 
entry and exit over time18, Figure 3 depicts the cumulative number of firms in the US (i.e. firm 
entries minus exits) into four nanobiotechnology industry subsectors: biopharmaceuticals, drug 
delivery, suppliers & instrumentation, and diagnostics.  Bio-pharmaceutical firms, the most 
prevalent subsector of the nanobiotechnology industry, were early entrants into specific areas of 
nanobiotechnology research, such as utilising liposomes for drug delivery. A pioneer was 
Liposome Technology Inc. (LTI), with the development of Doxil®: LTI was acquired by Alza 
which was in turn acquired by Johnson & Johnson8. The rate of entry into the biopharmaceutical 
subsector increased after the FDA approval of Doxil® in 1995, and further accelerated between 
2004 and 2008. (Fig. 3).  The drug delivery subsector experienced gradual firm entry over the 
first two decades, followed by a rapid increase between 2004 and 2008.  Rapid entry into the 
suppliers & instrumentation subsector began earlier, around 2000, though this began to plateau 
in 2005.  Diagnostics, the smallest subsector shown in Figure 3, increased gradually from 2000 
to 2011.     
Industries evolve over time in known patterns, moving from a fluid phase to a transitional phase 
to a specific phase; each phase has characteristic rates of product and process innovation, and 
associated changes in firm entry and exit, research and development management, 
organizational characteristics, market focus, and competitive focus18. In several studies of the 
evolution of industries, a dominant design – a standard set of product features or technological 
attributes that become expected by the marketplace – emerges after a period of rapid entry of 
firms and instigates consolidation of firms in the industry. Although easier to analyze in 
hindsight, our data suggests that one or more dominant designs may have emerged in the 
suppliers & instrumentation subsector (an example might be processes for the synthesis of 
nanoparticles). This shift in the phase of industry evolution is suggested by the rapid growth and 
subsequent plateau depicted in the suppliers & instrumentation curve in Figure 3. Consistent 
with this interpretation, we note higher consolidation (i.e. firm exits) in this industry subsector. 
Scientists and engineers in these firms should therefore be more focused on process attributes, 
such as reducing cost and increasing reliability, and less focused on developing new product 
features or technological attributes.   
The drug delivery subsector appears to be toward the end of the fluid phase of industry 
emergence. In this phase, there are still opportunities for radical innovation, and the focus is on 
competing on product features or technical attributes. That said, the rate of entry has reduced in 
this subsector, and potential dominant designs are emerging among drug delivery 
technologies19,20. Our data on the degree of integration of nanobiotechnology knowledge in 
biopharmaceutical firms suggests that they may only adopt a dominant design from the drug 
delivery firms, rather than contribute to forming it. Biopharmaceutical firms are likely to focus 
more on the new drug and less on the delivery mechanism, choosing to adopt and, where 
necessary, adapt mechanisms developed by drug delivery specialist firms.  Doxil® is a good 
example of the delivery mechanism being developed by a specialist nanobiotechnology drug 
delivery venture8. 
Conclusions 
Although the first firms to develop capabilities in both biotechnology and nanotechnology were 
multinational corporations, these capabilities often remained in ‘silos’ and were overshadowed 
by the multinational corporations’ existing capabilities. De novo firm entry intensified after 1995 
and appears to be the primary driver for innovation in such highly diverse fields. The US 
remains the dominant location for nanobiotechnology commercialization, with Germany a distant 
second.  In terms of industry subsectors, the drug delivery sub-sector appears to be coalescing 
around potential dominant designs, but still competes on technological attributes: as such, the 
focus is still on product innovation, and establishing a dominant design. In the suppliers & 
instrumentation subsector, the period of rapid entry appears to have concluded, suggesting that 
these firms should be focussing on process innovation and subsequent cost reduction.  
We argue that knowledge-based sectors drawing on a diverse range of novel inputs, such as 
biotechnology and nanotechnology, will be most likely to provide opportunities for radical 
innovation and economic growth. Integration of such disparate technological fields is not 
straightforward, however, especially for multinational corporations. Firms can increase their 
chances at benefiting from emerging industries such as nanobiotechnology by enhancing the 
exchange of ideas across technology fields and knowledge workers. Co-location of diverse 
groups, purposeful mixing of disparate expertise and insulation from an incremental innovation 
culture are recommended8,11,21. Hiring of scientists and engineers with an interdisciplinary 
education could also help bridge technology ‘silos’8,22. Such practices would accelerate the 
transition of the significant promise of nanobiotechnology into economic and social value.   
Governments can also influence innovation in industry by providing resources and by creating 
an environment encouraging innovation. Measures that have been proven most effective are 
government funding of research, ensuring a broad and strong system of education, and 
ensuring a robust and resilient infrastructure23. We have observed in our data here and in other 
studies that new entrants in emerging industries tend to be clustered in a few locations that 
might be said to have a strong and balanced ecology of research centers, talented human 
resources, excellent transportation, communication and other assets supporting innovation24. 
The increasing entry of firms outside of traditional biotechnology clusters, however, suggests 
that science policy can play an active role in this emerging industry, with star scientists at 
research universities seeding new clusters.  
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Figure 1. The evolution of the global nanobiotechnology industry by firm type. Firms are 
divided into three categories: De Novo, De Alio and multinational corporations. De Novo are 
firms where the difference between the founding year and year of acquisition of nanotechnology 
capability was 3 years or less. De Alio are firms where the difference between the founding year 








Figure 2. Evolution of the global nanobiotechnology industry by regions. The Australasia-
Asia category includes Asian countries as well as Australia, New Zealand and Israel. The North 







Figure 3. Evolution of selected nanobiotechnology subsectors in the US. 
 Box 1: Example of a highly integrated de novo firm: NanoSphere 
treatment 
 
 Nearly entire biotechnology or nanotechnology patent portfolio integrated
o Founder Chad Mirkin is a pioneer in the integration of nanotechnology with
biotechnology
o 46 out of 50 US patents incorporate both biotechnology and nanotechnology
o “We live at the boundaries of molecular diagnostics and nanotechnology” Bill
Moffit, former CEO Nanosphere.
 De Novo Nanobiotechnology Diagnostics Firm
o Earlier detection of disease and more targeted treatment
o World’s first diagnostic  test for sepsis, shortening time from 3 days to 3 hours
o Utilizing functionalized gold nanoparticles to detect nucleic acid or protein
targets
o Multiple tests under development with more accurate, more specific  results
 Spun out of Northwestern University (USA) in 2000
o US$5 million in revenues in 2012
o Approximately US$300 million invested since founding
o Currently scaling up manufacturing facilities
o Initial Public Offering (IPO) on the NASDAQ in 2007
o Market capitalization of US$155 million in 2013





BioPharma Firms involved in multiple sub-segments 
such as pharmaceuticals, drug delivery, 
contract research. 
Roche, Merck, Bayer, 
Johnson & Johnson, DuPont, 
Celator 
Drug Delivery Firms specializing in drug delivery C-Sixty, enGene, 3M, 
Siemens 
Diagnostics Firms specializing in human diagnostics 
and imaging  
NanoSphere,  NanoGen, 
PanBio, NanoProbes  
Suppliers & 
Instrumentation 
Firms supplying nano-materials, 
instrumentation, consumables, lab 
equipment 
Dow, Degussa, Agilent, 
Toray, Hitachi 
Medical Devices Firms providing medical devices such as 
wound care products, blood care products 
etc.  
Wilson Greatbatch Inc, 
Haemonetics 
Biomaterials Firms focussing on dental implants, 
orthopedic implants etc. 
Allvivo Vascular, Mnemo 
Sciences, Nanovis 
Bioinformatics Firms specializing in bioinformatics and 
providing drug discovery services. 
HP, IBM 
1
 We classify multinational corporations (MNCs) based on their applications in the 
nanobiotechnology space.  For example, 3M’s nanobiotechnology focus is on asthma inhaler 
innovation and thus 3M is classified in the drug delivery subcategory.    
Supplementary Information 
We created three distinct samples (cohorts) for longitudinal analysis over the course of evolution 
of the nanobiotechnology industry: these cohorts consist of firms with both biotechnology and 
nanotechnology capabilities in 2005, 2008 and 2011.  We used the DMS IndustryAnalyser, DMS 
NewsAnalyser, and Medtrack databases to identify a pool of biotechnology firms targeting 
human health which potentially held nanotechnology capabilities, whether integrated or in 
separate research divisions.
 
 DMS IndustryAnalyser and DMS NewsAnalyser went out of service 
in 2009, necessitating the use of a new database to create the 2011 cohort.  Relevant firms from 
the 2011 cohort were added to the earlier cohorts, creating a robust sample.   Similarly, firms 
identified by DMS in the 2008 cohort (but not by Medtrack) were added to the 2011 sample, 
when proof was found that they still had relevant capabilities.  
Next, we verified the existence and timing of development of both sets of capabilities 
through web searches, press releases, publications, and US patents. Nanotechnology patents were 
identified using keywords adapted from recent studies
1,2
 and biotechnology patents were
identified using standard guidelines based on patent sub-classes
3
. Using the patent filing date
from the first of the selected patents (assigned to the company or its relevant subsidiaries) and 
comparing with the founding year of the firm, we were able to classify firms as de novo if the 
difference between the founding year and year of acquisition of nanotechnology capability was 3 
years or less. Firms with more than 3 years difference between founding and year of acquisition 
of nanotechnology capabilities were identified as de alio or incumbent firms. In cases where 
firms had not yet had patents assigned to them, press releases, company documents, scientific 
publications and industry reports were used to identify the initial year of development of 
nanotechnology capabilities. These additional data sources allowed us to retrospectively 
supplement each cohort if these sources indicated such capability development prior to their date 
of entry in the three databases used. This retrospective analysis thus enables our sample to 
comprehensively represent the evolution of this industry across regions (Table 1).
 
We 
acknowledge that there may have been some exits prior to 2005 which would not necessarily 
have been captured by our methodology.  
Patent data also was used as a measure of the level of integration of biotechnology and 
nanotechnology capabilities within a firm. We gathered all biotechnology and all 
nanotechnology US patents issued to the firms in our sample and identified patents overlapping 
both searches. As of 2011, 82 firms out of the 507 nanobiotechnology firms in our global sample 
had issued US patents which integrated biotechnology capabilities with nanotechnology 
capabilities.  The level of nanobiotechnology integration was higher in de novo firms than in 
multinational corporations. 
Table 1: Global distribution of nanobiotechnology firms 
Cohort/ Region Australasia-Asia* Europe North America
#
Total 
2005 39 (14%) 73 (25%) 175 (61%) 287 
2008 62 (14%) 116 (27%) 255 (59%) 433 
2011 72 (14%) 147 (29%) 288 (57%) 507 
*Asian countries as well as Australia, New Zealand and Israel.
# North America includes USA, Canada and 3 South American firms which entered in 2011. 
By treating all firms as fundamental experiments in the evolution of an emerging industry 
and by attempting to capture all firms in the industry over time, our study adds to existing 
industry evolution literature by studying a case of technology confluence as it unfolds. Our 
advancement in granularity includes tracking firm entry and exit, firm type, and application 
  
focus. Using data from company documents, industry reports and the DMS and Medtrack 
databases, we are able to classify the biotechnology firms as belonging to specific sub-sectors 
which helps us to examine the evolution of nanobiotechnology at the level of the sub-sector. 
Previous studies have concentrated on bibliometric assessments of scientific publications or 
patents to separately examine the biotechnology and nanotechnology industries
4
, or to examine 
specific case studies within the nanobiotechnology industry regarding the generation of 
interdisciplinary knowledge
5
. Patents, while critical to the study of invention, do not adequately 
represent innovation.  One study which did examine firms commercializing nanomedicine 
identified 207 firms globally as of 2004: the study focused on new products which had been 




  A later study identified 308 medical nanotechnology 
firms as of 2007
7
.   
We extend existing studies in several ways.  First, we focus on tracking the entry of firms 
into the emerging nanobiotechnology industry, and are very comprehensive in our identification 
of global nanobiotechnology firms, resulting in a broader geographical distribution than found in 
previous studies.  Second, we also are more specific to nanotechnology by limiting our inclusion 
criteria to firms with nanoscale capabilities defined as less than 300 nm, as opposed to the 1000 
nm criteria utilised by the earlier studies
6,7
. Third, we include nanobiotechnology firms which do 
not yet have issued patents, where there is other public evidence of both biotechnology and 
nanotechnology capabilities.  Fourth, by adopting keywords used to search broadly for 
nanotechnology patents
1,2
, while also tracking all firm biotechnology patents, we are able to 
enhance our industry evolution analysis and also provide insight on integration of biotechnology 
and nanotechnology capabilities.  Together, this approach enables us to contribute to a nuanced, 
comprehensive picture of the emergence and evolution of the global nanobiotechnology industry. 
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